IL265192A - Crystalline forms of lysyl oxidase inhibitor-like 2 and methods of preparation - Google Patents
Crystalline forms of lysyl oxidase inhibitor-like 2 and methods of preparationInfo
- Publication number
- IL265192A IL265192A IL265192A IL26519219A IL265192A IL 265192 A IL265192 A IL 265192A IL 265192 A IL265192 A IL 265192A IL 26519219 A IL26519219 A IL 26519219A IL 265192 A IL265192 A IL 265192A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- making
- methods
- crystalline forms
- lysyl oxidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384596P | 2016-09-07 | 2016-09-07 | |
| PCT/US2017/050332 WO2018048943A1 (en) | 2016-09-07 | 2017-09-06 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL265192A true IL265192A (en) | 2019-05-30 |
Family
ID=61561660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265192A IL265192A (en) | 2016-09-07 | 2019-03-06 | Crystalline forms of lysyl oxidase inhibitor-like 2 and methods of preparation |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774069B2 (enExample) |
| EP (1) | EP3510023B1 (enExample) |
| JP (1) | JP7079772B2 (enExample) |
| KR (1) | KR102587178B1 (enExample) |
| CN (1) | CN109983006B (enExample) |
| AU (1) | AU2017324445A1 (enExample) |
| BR (1) | BR112019004517A2 (enExample) |
| CA (1) | CA3036064A1 (enExample) |
| EA (1) | EA201990621A1 (enExample) |
| IL (1) | IL265192A (enExample) |
| MA (1) | MA46204A (enExample) |
| MX (1) | MX390964B (enExample) |
| SG (1) | SG11201901999XA (enExample) |
| WO (1) | WO2018048943A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144702A1 (en) * | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| WO2016144703A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| CN108884049A (zh) * | 2016-02-09 | 2018-11-23 | 法玛克亚公司 | 喹啉酮赖氨酰氧化酶样2抑制剂及其用途 |
| MX2019002612A (es) | 2016-09-07 | 2019-08-21 | Pharmakea Inc | Usos de un inhibidor de lisil-oxidasa tipo 2. |
| MX390964B (es) * | 2016-09-07 | 2025-03-21 | Pharmakea Inc | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| CN114487139B (zh) * | 2020-10-27 | 2025-01-14 | 鲁南制药集团股份有限公司 | 一种盐酸西替利嗪有关物质的检测方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| IE56702B1 (en) * | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| MXPA02007047A (es) | 2000-01-18 | 2002-12-13 | Pfizer Prod Inc | Antagonista del factor liberador de corticotropina. |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CN1787817B (zh) | 2003-05-19 | 2011-09-07 | Irm责任有限公司 | 免疫抑制剂化合物及组合物 |
| WO2005082370A1 (en) | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
| CA2558568A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2005092836A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| CN1976907A (zh) | 2004-04-30 | 2007-06-06 | 武田药品工业株式会社 | 杂环酰胺化合物及其作为mmp－13抑制剂的用途 |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| JP2008512441A (ja) | 2004-09-10 | 2008-04-24 | ファイザー・プロダクツ・インク | ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法 |
| BRPI0515143A (pt) | 2004-09-10 | 2008-07-08 | Pfizer Prod Inc | usos de derivados azabicìclicos de piridiloximetila e benzisoxazol para a preparação de uma composição farmacêutica para o tratamento dos distúrbios de humor |
| WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| US7759493B2 (en) | 2005-01-31 | 2010-07-20 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| CA2618586A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ITMI20051943A1 (it) * | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2007087250A2 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| EP2121703A4 (en) | 2006-08-18 | 2011-12-28 | Astrazeneca Ab | THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| ES2700141T3 (es) | 2007-08-02 | 2019-02-14 | Gilead Biologics Inc | Anticuerpos inhibidores LOXL2 y usos de los mismos |
| KR20130031233A (ko) | 2009-07-28 | 2013-03-28 | 아나코르 파마슈티칼스 인코포레이티드 | 삼치환된 붕소 함유 분자 |
| EP2467162A4 (en) | 2009-08-21 | 2013-10-02 | Gilead Biologics Inc | THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS |
| US8680246B2 (en) | 2010-02-04 | 2014-03-25 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) |
| US8513230B2 (en) | 2010-03-05 | 2013-08-20 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| RU2014120166A (ru) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина |
| BR112014026399B1 (pt) | 2012-04-25 | 2022-11-01 | Raqualia Pharma Inc | Composto de fórmula (ii), composição farmacêutica, uso e processo para preparar uma composição farmacêutica |
| JP2016500700A (ja) | 2012-10-30 | 2016-01-14 | ギリアード サイエンシーズ， インコーポレイテッド | リシルオキシダーゼ様２（ｌｏｘｌ２）に関する治療および診断方法 |
| CN104854086B (zh) | 2012-12-18 | 2017-06-27 | Ea制药株式会社 | 杂环酰胺衍生物和含有其的药物 |
| JP2018522812A (ja) | 2014-08-05 | 2018-08-16 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | カスパーゼ−６のモジュレーター |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| WO2016128529A1 (en) | 2015-02-15 | 2016-08-18 | F. Hoffmann-La Roche Ag | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
| WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| WO2016144703A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| MX390964B (es) | 2016-09-07 | 2025-03-21 | Pharmakea Inc | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. |
| MX2019002612A (es) | 2016-09-07 | 2019-08-21 | Pharmakea Inc | Usos de un inhibidor de lisil-oxidasa tipo 2. |
-
2017
- 2017-09-06 MX MX2019002615A patent/MX390964B/es unknown
- 2017-09-06 US US16/331,095 patent/US10774069B2/en active Active
- 2017-09-06 EA EA201990621A patent/EA201990621A1/ru unknown
- 2017-09-06 EP EP17849479.5A patent/EP3510023B1/en active Active
- 2017-09-06 BR BR112019004517-1A patent/BR112019004517A2/pt not_active IP Right Cessation
- 2017-09-06 JP JP2019512640A patent/JP7079772B2/ja active Active
- 2017-09-06 CN CN201780068733.0A patent/CN109983006B/zh active Active
- 2017-09-06 CA CA3036064A patent/CA3036064A1/en active Pending
- 2017-09-06 SG SG11201901999XA patent/SG11201901999XA/en unknown
- 2017-09-06 MA MA046204A patent/MA46204A/fr unknown
- 2017-09-06 WO PCT/US2017/050332 patent/WO2018048943A1/en not_active Ceased
- 2017-09-06 AU AU2017324445A patent/AU2017324445A1/en not_active Abandoned
- 2017-09-06 KR KR1020197009870A patent/KR102587178B1/ko active Active
-
2019
- 2019-03-06 IL IL265192A patent/IL265192A/en unknown
-
2020
- 2020-08-03 US US16/983,759 patent/US11459309B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7079772B2 (ja) | 2022-06-02 |
| CN109983006A (zh) | 2019-07-05 |
| CN109983006B (zh) | 2022-02-25 |
| US20190202805A1 (en) | 2019-07-04 |
| EA201990621A1 (ru) | 2019-09-30 |
| AU2017324445A1 (en) | 2019-04-11 |
| MX2019002615A (es) | 2019-10-15 |
| US11459309B2 (en) | 2022-10-04 |
| JP2019532919A (ja) | 2019-11-14 |
| SG11201901999XA (en) | 2019-04-29 |
| US10774069B2 (en) | 2020-09-15 |
| KR102587178B1 (ko) | 2023-10-06 |
| BR112019004517A2 (pt) | 2019-08-13 |
| WO2018048943A1 (en) | 2018-03-15 |
| EP3510023B1 (en) | 2024-06-19 |
| EP3510023A1 (en) | 2019-07-17 |
| CA3036064A1 (en) | 2018-03-15 |
| MA46204A (fr) | 2021-03-17 |
| EP3510023A4 (en) | 2020-03-18 |
| KR20190052040A (ko) | 2019-05-15 |
| MX390964B (es) | 2025-03-21 |
| US20200361901A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265232A (en) | Uses of lysyl oxidase-like inhibitor 2 | |
| IL254236A0 (en) | Fluorine-converted lysyl oxidase-like 2 inhibitors and their uses | |
| IL272557A (en) | Sulfonylureas and sulfonythioureas as NLRP3 inhibitors | |
| EP3265445A4 (en) | Lysyl oxidase-like 2 inhibitors and uses thereof | |
| IL270872A (en) | Crystalline forms of an FGFR inhibitor and a process for their preparation | |
| IL302528B1 (en) | Crystalline solid forms of Ia and III-XV of the Bat inhibitor and their uses | |
| IL261606A (en) | Inhibitors of transfected menin-mll and methods of use | |
| PL3728254T3 (pl) | Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1 | |
| IL268981B1 (en) | Solid forms and combined preparations containing beta-lactamase inhibitor and uses thereof | |
| IL267291B (en) | Actonucleotidase inhibitors and methods of using them | |
| HUE055978T2 (hu) | Piridopirimidinon CDK2/4/6 inhibitorok | |
| EP3317258A4 (en) | LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF | |
| EP3209815A4 (en) | Corrosion inhibitors and related compositions and methods | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| EP3325462A4 (en) | INHIBITORS OF LYSYL OXIDASE-LIKE 2 AND USES OF SAID INHIBITORS | |
| IL273727A (en) | Lysyl oxidase inhibitors | |
| PT3543240T (pt) | Inibidor de urat1 e utilização deste | |
| GB2583609B (en) | Cleanout tools and related methods of operation | |
| SG10202006699XA (en) | Inhibition of allergic reaction using an il-33 inhibitor | |
| SG11201608226YA (en) | Oligonucleotide compositions and methods of making the same | |
| ZA201807056B (en) | Conjugated c1 esterase inhibitor and uses thereof | |
| HUE044559T2 (hu) | Lerakódást gátló készítmények és alkalmazási eljárásaik | |
| PL4218753T3 (pl) | Nowe inhibitory lipazy i ich zastosowania | |
| HK40009411A (en) | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | |
| HK40009578A (en) | Uses of a lysyl oxidase-like 2 inhibitor |